ArticleEClinicalMedicine2024

Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial.

Suzana Margareth Lobo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.